Business Wire

SOSAFE

Share
SoSafe Adds Two US Cybersecurity Luminaries to Its Board Amidst Rapid Go-to-market Expansion

SoSafe, Europe’s leading vendor for security awareness and training, today announced it has appointed two world-class cybersecurity industry leaders to its board: Tech executive Zeynep Inanoglu Ozdemir, former CMO at Palo Alto Networks, and Bhagwat Swaroop, experienced executive in the cybersecurity space and current President of Digital Security Solutions at Entrust.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230523005033/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Europe’s leading security awareness and training vendor SoSafe adds Zeynep Inanoglu Ozdemir, former CMO at Palo Alto Networks, to their board. (Photo: Business Wire)

Niklas Hellemann, CEO of SoSafe: “At SoSafe, we are at the forefront of security awareness innovation. Bringing two world-class industry leaders like Zeynep and Bhagwat for our board will strengthen our market expertise even further, boosting international expansion and product excellence. Advances in generative AI will inevitably lead to an escalation of the cyber threat landscape, particularly from a human risk perspective. We are delighted to welcome two highly experienced cybersecurity experts to our board, helping us to navigate this paradigm shift. SoSafe’s whole management team is very much looking forward to working with them.”

Zeynep Inanoglu Ozdemir has held key marketing leadership roles at Palo Alto Networks during a four-year period of rapid growth and transformation. As CMO, she has been responsible for launching an award-winning brand campaign for the company as well as pioneering the XDR category in cybersecurity at large. Previously, Ozdemir has worked at Palantir Technologies and Google, and currently sits on the board at iKSV, Turkey’s predominant arts and culture foundation. She holds a PhD in speech processing from Cambridge University, Machine Intelligence Lab, and a bachelor's degree in electrical engineering from Harvard University. Her deep expertise in category creation, data-driven marketing and growth strategies will be of great value to our board at SoSafe.

“Human-level risk management and security awareness programs are key capabilities in an increasingly automated threat landscape”, says Ozdemir. “I am very excited work with SoSafe to further their mission to drive secure behavior at scale.”

Bhagwat Swaroop is the President of Digital Security Solutions at Entrust and brings more than 20 years of leadership experience driving growth in global high-tech companies to the board. He was most recently president and General Manager of One Identity, where he led the company’s turnaround to a cloud-based cybersecurity company. Prior to One Identity, Swaroop was a Corporate Officer and Executive Vice President at Proofpoint responsible for driving company’s rapid growth and helped make Proofpoint the market leader in email security. Previously he held leadership positions at Symantec, NetApp, McKinsey, and Intel. He is a seasoned strategic leader and brings a deep understanding of the enterprise security landscape, technology ecosystem and cloud driven business models. He is a sought expert and public speaker on cybersecurity, cloud computing and national policy topics. “Security awareness training has become a foundational capability to make the human layer more resilient to the constant phishing attempts.” states Swaroop. “I was impressed by SoSafe’s deep focus on fusing behavioral science with cybersecurity awareness solutions. I am looking forward to working with the SoSafe leadership team in the next phase of their growth journey”.

With these new additions to its board, European security awareness leader SoSafe underlines its commitment for international expansion and product innovation.

_______________

About SoSafe

SoSafe empowers organizations to build a security culture and mitigate risk with its GDPR-compliant awareness programs. The company was founded in Cologne, Germany, in 2018 by Dr Niklas Hellemann, Lukas Schaefer, and Felix Schuerholz. Today, it serves more than 3000 customers worldwide and is the market leader in security awareness and training in the DACH region. As one of the leading second-generation awareness platforms, they are powered by behavioral science and smart algorithms and focus on user engagement and the needs of the customer. In doing so, SoSafe delivers engaging, personalized learning experiences and smart attack simulations that turn employees into active assets against online threats. The SoSafe team consists of more than 370 employees at five locations: Cologne (headquarters), Amsterdam, Berlin, London, and Paris.

Website: www.sosafe-awareness.com/

LinkedIn: https://www.linkedin.com/company/sosafe-cyber-security/

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230523005033/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release

AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th

CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release

Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release

Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release

52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society

Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release

- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye